
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7507779/publications.pdf Version: 2024-02-01



ANNA ROONEN

#	Article	IF	CITATIONS
1	Response to: â€~Correspondence on â€~Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Zheng. Annals of the Rheumatic Diseases, 2023, 82, e94-e94.	0.9	2
2	Response to: â€~Correspondence on â€~Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Gong and Zhang and Lin <i>et al</i> . Annals of the Rheumatic Diseases, 2023, 82, e143-e143.	0.9	1
3	2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2023, 82, 48-56.	0.9	71
4	Instrument selection for the ASAS core outcome set for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2023, 82, 763-772.	0.9	18
5	Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a <scp>52â€Week</scp> , Randomized, Controlled Trial. Arthritis Care and Research, 2022, 74, 451-460.	3.4	10
6	Do tender joints in active psoriatic arthritis reflect inflammation assessed by ultrasound and magnetic resonance imaging?. Rheumatology, 2022, 61, 723-733.	1.9	10
7	Outcomes of Care Among Patients With Gout in Europe: A Cross-sectional Survey. Journal of Rheumatology, 2022, 49, 312-319.	2.0	3
8	Treat-to-target in axial spondyloarthritis: an observational study in daily practice. Rheumatology, 2022, 61, 1396-1407.	1.9	5
9	How do clinical and socioeconomic factors impact on work disability in early axial spondyloarthritis? Five-year data from the DESIR cohort. Rheumatology, 2022, 61, 2034-2042.	1.9	6
10	Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink. Rheumatology, 2022, 61, 1448-1458.	1.9	12
11	Individual-level and country-level socio-economic factors and health outcomes in spondyloarthritis: analysis of the ASAS-perSpA study. Rheumatology, 2022, 61, 2043-2053.	1.9	5
12	Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis. Rheumatology, 2022, 61, 2054-2062.	1.9	4
13	Health-related quality of life of patients with a recent fracture attending a fracture liaison service: a 3-year follow-up study. Osteoporosis International, 2022, 33, 577-588.	3.1	11
14	Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment. Osteoporosis International, 2022, , 1.	3.1	0
15	Biological Disease-Modifying Antirheumatic Drugs and Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: A Danish Cohort Study. American Journal of Medicine, 2022, 135, 879-888.e3.	1.5	7
16	Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients. RMD Open, 2022, 8, e001979.	3.8	2
17	Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open, 2022, 8, e002170.	3.8	32
18	Challenges in the management of older patients with inflammatory rheumatic diseases. Nature Reviews Rheumatology, 2022, 18, 326-334.	8.0	19

#	Article	IF	CITATIONS
19	Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open, 2022, 8, e002168.	3.8	35
20	Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout. BMC Medical Informatics and Decision Making, 2022, 22, 95.	3.0	2
21	Exploring discordance between Health Literacy Questionnaire scores of people with RMDs and assessment by treating health professionals. Rheumatology, 2022, 62, 52-64.	1.9	3
22	New indicator for discordance between patient-reported and traditional disease activity outcomes in patients with early rheumatoid arthritis. Rheumatology, 2022, 62, 108-115.	1.9	9
23	Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open, 2022, 8, e002167.	3.8	28
24	Work-related support in clinical care for patients with a chronic disease: development of an intervention. Journal of Occupational Rehabilitation, 2022, 32, 705-717.	2.2	3
25	A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service. Journal of Medical Economics, 2022, 25, 829-839.	2.1	2
26	Effect modification by contextual factors of urate-lowering therapy on serum urate in people with gout: A systematic review with meta-regression analysis. Seminars in Arthritis and Rheumatism, 2022, 56, 152049.	3.4	0
27	Sex Differences in the Clinical Profile Among Patients With Gout: Cross-sectional Analyses of an Observational Study. Journal of Rheumatology, 2021, 48, 286-292.	2.0	19
28	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. Annals of the Rheumatic Diseases, 2021, 80, 518-526.	0.9	54
29	lxekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. Journal of Rheumatology, 2021, 48, 188-197.	2.0	7
30	An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis. Pharmacoeconomics, 2021, 39, 181-209.	3.3	63
31	Addressing Health Literacy Needs in Rheumatology: Which Patient Health Literacy Profiles Need the Attention of Health Professionals?. Arthritis Care and Research, 2021, 73, 100-109.	3.4	19
32	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. Annals of the Rheumatic Diseases, 2021, 80, 242-249.	0.9	6
33	Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study. Annals of the Rheumatic Diseases, 2021, 80, 423-431.	0.9	21
34	Costs of disease: The perspective matters. International Journal of Rheumatic Diseases, 2021, 24, 293-296.	1.9	0
35	Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider. RMD Open, 2021, 7, e001522.	3.8	9
36	A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. Journal of Rheumatology, 2021, 48, 1259-1267.	2.0	8

#	Article	IF	CITATIONS
37	Heterogeneity of Lipid and Protein Cartilage Profiles Associated with Human Osteoarthritis with or without Type 2 Diabetes Mellitus. Journal of Proteome Research, 2021, 20, 2973-2982.	3.7	5
38	Frailty in relation to psychoâ€social factors in elderly patients with rheumatoid arthritis: A crossâ€sectional mixed qualitativeâ€quantitative study. International Journal of Rheumatic Diseases, 2021, 24, 766-773.	1.9	7
39	The Relationship Between Walking Speed and the Energetic Cost of Walking in Persons With Multiple Sclerosis and Healthy Controls: A Systematic Review. Neurorehabilitation and Neural Repair, 2021, 35, 486-500.	2.9	12
40	The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis. Osteoporosis International, 2021, 32, 1517-1530.	3.1	51
41	EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 2021, 80, 1116-1123.	0.9	13
42	OP0316â€ASSOCIATION BETWEEN INDIVIDUAL AND COUNTRY-LEVEL SOCIOECONOMIC FACTORS AND WOR PARTICIPATION IN PERIPHERAL AND AXIAL SPONDYLOARTHRITIS: ANALYSIS OF THE ASAS perSpA Study. Annals of the Rheumatic Diseases, 2021, 80, 193.2-193.	۲ 0.9	0
43	AB0915-PAREâ€DEVELOPMENT AND USABILITY OF A WEB-BASED PATIENT-TAILORED TOOL TO SUPPORT ADHERENCE TO URATE-LOWERING THERAPY IN GOUT PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 1479.1-1479.	0.9	1
44	Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Annals of the Rheumatic Diseases, 2021, 80, 1436-1444.	0.9	58
45	OP0169-PAREâ€DEVELOPMENT OF POINTS TO CONSIDER WHEN SUPPORTING PERSONS WITH REUMATIC AND MUSCULOSKELETAL DISEASES TO PARTICIPATE IN HEALTHY AND SUSTAINABLE PAID WORK. Annals of the Rheumatic Diseases, 2021, 80, 101.1-101.) 0.9	1
46	POS0951â€ASSOCIATION BETWEEN INDIVIDUAL AND COUNTRY-LEVEL SOCIOECONOMIC FACTORS AND HEAL OUTCOMES IN AXIAL AND PERIPHERAL SPONDYLOARTHRITIS: ANALYSIS OF THE ASAS PERSPA STUDY. Annals of the Rheumatic Diseases, 2021, 80, 739-740.	_TH 0.9	0
47	Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial. RMD Open, 2021, 7, e001615.	3.8	13
48	POS0503â€THE DISCORDANCE BETWEEN PATIENT-REPORTED AND CLINICAL/BIOLOGICAL OUTCOMES COULD HELP IN PREDICTING FUTURE DISEASE IMPACT IN PATIENTS WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 484.1-484.	0.9	2
49	OPO324-PAREâ€PATIENT INFORMATION IN TIMES OF CRISIS: LESSONS LEARNED FROM COVID-19 COMMUNICATION IN RHEUMATOLOGY. Annals of the Rheumatic Diseases, 2021, 80, 198.1-198.	0.9	0
50	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. Seminars in Arthritis and Rheumatism, 2021, 51, 601-606.	3.4	7
51	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. Seminars in Arthritis and Rheumatism, 2021, 51, 593-600.	3.4	13
52	Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort. RMD Open, 2021, 7, e001685.	3.8	6
53	Association between individual and country-level socioeconomic factors and work participation in spondyloarthritis including psoriatic arthritis: Analysis of the ASAS-perSpA study. Seminars in Arthritis and Rheumatism, 2021, 51, 804-812.	3.4	5
54	The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. Seminars in Arthritis and Rheumatism, 2021, 51, 1320-1330.	3.4	25

#	Article	IF	CITATIONS
55	The ASAS-OMERACT core domain set for axial spondyloarthritis. Seminars in Arthritis and Rheumatism, 2021, 51, 1342-1349.	3.4	35
56	Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey. Journal of Rheumatology, 2021, 48, 1810-1814.	2.0	3
57	Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group✰. Seminars in Arthritis and Rheumatism, 2021, 51, 919-924.	3.4	7
58	Performance of three composite measures for disease activity in peripheral spondyloarthritis. Journal of Rheumatology, 2021, , jrheum.210075.	2.0	4
59	Does Including Pain, Fatigue, and Physical Function When Assessing Patients with Early Rheumatoid Arthritis Provide a Comprehensive Picture of Disease Burden?. Journal of Rheumatology, 2021, 48, 174-178.	2.0	14
60	Improvement of osteoporosis Care Organized by Nurses: ICON study - Protocol of a quasi-experimental study to assess the (cost)-effectiveness of combining a decision aid with motivational interviewing for improving medication persistence in patients with a recent fracture being treated at the fracture liaison service. BMC Musculoskeletal Disorders, 2021, 22, 913.	1.9	8
61	Development and Evaluation of a Clinic for Elderly Patients with Rheumatoid Arthritis and Multimorbidity: A Pilot Study. ACR Open Rheumatology, 2021, 3, 34-40.	2.1	4
62	Comparative Study of Realâ€Life Management Strategies in Gout: Data From Two Protocolized Gout Clinics. Arthritis Care and Research, 2020, 72, 1169-1176.	3.4	4
63	Understanding patients' preferences for osteoporosis treatment: the impact of patients' characteristics on subgroups and latent classes. Osteoporosis International, 2020, 31, 85-96.	3.1	8
64	What do we measure with 28-joint DAS in elderly patients? An explorative analysis in the NOR-DMARD study. Rheumatology, 2020, 59, 1622-1625.	1.9	4
65	Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA study. Rheumatology, 2020, 59, 1632-1639.	1.9	3
66	Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT). Arthritis Research and Therapy, 2020, 22, 225.	3.5	8
67	Cost assessment of health interventions and diseases. RMD Open, 2020, 6, e001287.	3.8	11
68	Comparative construct validity of three presenteeism instruments in workers with musculoskeletal complaints: a prospective cohort study. RMD Open, 2020, 6, e001281.	3.8	4
69	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. Annals of the Rheumatic Diseases, 2020, 79, 1423-1431.	0.9	11
70	Long-term sickness absence in a working population: development and validation of a risk prediction model in a large Dutch prospective cohort. BMC Public Health, 2020, 20, 699.	2.9	10
71	Drug utilization in the Maastricht Study. Medicine (United States), 2020, 99, e18524.	1.0	1
72	Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial. Annals of the Rheumatic Diseases, 2020, 79, 556-565.	0.9	17

#	Article	IF	CITATIONS
73	Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group. Annals of the Rheumatic Diseases, 2020, 79, 1269-1276.	0.9	3
74	(Health-Related) Quality of Life as an Outcome in Studies of Axial Spondyloarthritis. Rheumatic Disease Clinics of North America, 2020, 46, 379-393.	1.9	13
75	Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporosis International, 2020, 31, 1645-1669.	3.1	49
76	Validation and implementation of a patient-reported experience measure for patients with rheumatoid arthritis and spondyloarthritis in the Netherlands. Clinical Rheumatology, 2020, 39, 2889-2897.	2.2	8
77	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2020, 79, 193-201.	0.9	59
78	Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial. Clinical Gastroenterology and Hepatology, 2020, 18, 1744-1752.	4.4	49
79	THU0370â€CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL Annals of the Rheumatic Diseases, 2020, 79, 417.1-417.	0.9	6
80	Health technology assessment: a framework. RMD Open, 2020, 6, e001289.	3.8	17
81	FRI0081â€WERE FRAIL RA PATIENTS AT YOUNGER AGE MORE LONELY, DEPRESSED OR ANXIOUS THAN NON-FI RA PATIENTS?. Annals of the Rheumatic Diseases, 2020, 79, 617.1-618.	RAIL 0.9	0
82	Steps in implementing a health economic evaluation. RMD Open, 2020, 6, e001288.	3.8	5
83	Patient engagement in health technology assessment (HTA) and the regulatory process: what about rheumatology?. RMD Open, 2020, 6, .	3.8	1
84	Validation of two frailty questionnaires in older patients with rheumatoid arthritis: a cross-sectional study. Clinical and Experimental Rheumatology, 2020, 38, 523-528.	0.8	6
85	The Association Between Î ² -Blocker Use and Cardiorespiratory Fitness: The Maastricht Study. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 37-45.	2.0	6
86	Secular trends in major osteoporotic fractures among 50+ adults in Denmark between 1995 and 2010. Osteoporosis International, 2019, 30, 2217-2223.	3.1	23
87	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. Annals of the Rheumatic Diseases, 2019, 78, 1472-1479.	0.9	7
88	<p>Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment</p> . Patient Preference and Adherence, 2019, Volume 13, 1199-1211.	1.8	16
89	Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 394, 1993-2001.	13.7	78
90	Depression in ankylosing spondylitis and the role of disease-related and contextual factors: a cross-sectional study. Arthritis Research and Therapy, 2019, 21, 215.	3.5	26

#	Article	IF	CITATIONS
91	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. Journal of Rheumatology, 2019, 46, 1159-1163.	2.0	11
92	Treatment of Central Sensitization in Patients With Rheumatoid Arthritis: a Narrative Overview. Current Treatment Options in Rheumatology, 2019, 5, 179-189.	1.4	2
93	Economic Evaluations in Axial Spondyloarthritis. , 2019, , 259-279.		2
94	Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA). Annals of the Rheumatic Diseases, 2019, 78, 486-493.	0.9	24
95	Considerations for Evaluating and Recommending Worker Productivity Outcome Measures: An Update from the OMERACT Worker Productivity Group. Journal of Rheumatology, 2019, 46, 1401-1405.	2.0	13
96	OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. Journal of Rheumatology, 2019, 46, 1409-1414.	2.0	14
97	Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI. RMD Open, 2019, 5, e000872.	3.8	6
98	OP0238â€WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND TREATED WITH IXEKIZUMAB FOR 16 WEEKS: RESULTS FROM COAST-V AND COAST-W. , 2019, , .		0
99	AB1321â€PSYCHOMETRIC PROPERTIES OF THE ASAS HEALTH INDEX IN PATIENTS WITH ACTIVE AS/RADIOGRAF AXIAL SPA WHO HAVE PRIOR INADEQUATE RESPONSE/INTOLERANCE TO TNF INHIBITORS IN A PHASE 3 TRIAL. , 2019, , .	РНІС	0
100	THU0697-HPRâ€CONTENT OF AND RHEUMATOLOGISTS' AND NURSES' OPINIONS ON A NURSE-LED TE HELPLINE. , 2019, , .	LEPHONE	0
101	THU0358â€DEVELOPMENT OF A SET OF ASAS QUALITY STANDARDS FOR ADULTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
102	OP0180â€LOW-DOSE PREDNISOLONE IN PATIENTS WITH HAND OSTEOARTHRITIS (HOPE): RESULTS FROM A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL. , 2019, , .		0
103	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. Arthritis Care and Research, 2019, 71, 1556-1565.	3.4	43
104	Consumption of dairy products in relation to the presence of clinical knee osteoarthritis: The Maastricht Study. European Journal of Nutrition, 2019, 58, 2693-2704.	3.9	13
105	Development, usability and acceptability of an integrated eHealth system for spondyloarthritis in the Netherlands (SpA-Net). RMD Open, 2019, 5, e000860.	3.8	16
106	Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health. Journal of Rheumatology, 2019, 46, 1415-1420.	2.0	7
107	Rheumatologists' Views and Experiences in Managing Rheumatoid Arthritis in Elderly Patients: A Qualitative Study. Journal of Rheumatology, 2018, 45, 590-594.	2.0	14
108	Association of type 2 diabetes mellitus with self-reported knee pain and clinical knee osteoarthritis: The Maastricht Study. Diabetes and Metabolism, 2018, 44, 296-299.	2.9	9

#	Article	IF	CITATIONS
109	Contextual factors influence work outcomes in employed patients with ankylosing spondylitis starting etanercept: 2-year results from AS@Work. Rheumatology, 2018, 57, 791-797.	1.9	14
110	Is Anti–Citrullinated Protein Antibody–Positive Rheumatoid Arthritis Still a More Severe Disease Than Anti–Citrullinated Protein Antibody–Negative Rheumatoid Arthritis? A Longitudinal Cohort Study in Rheumatoid Arthritis Patients Diagnosed From 2000 Onward. Arthritis Care and Research, 2018, 70, 987-996.	3.4	38
111	Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingnessâ€ŧoâ€₽ay Approach. Arthritis Care and Research, 2018, 70, 608-616.	3.4	1
112	Medication adherence among patients with gout: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2018, 47, 689-702.	3.4	108
113	Disease burden of knee osteoarthritis patients with a joint replacement compared to matched controls: a population-based analysis of a Dutch medical claims database. Osteoarthritis and Cartilage, 2018, 26, 202-210.	1.3	6
114	Employment and the role of personal factors among patients with ankylosing spondylitis: a Dutch cross-sectional case-control study. RMD Open, 2018, 4, e000680.	3.8	12
115	Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. RMD Open, 2018, 4, e000755.	3.8	15
116	EULAR â€~points to consider' for the conduction of workforce requirement studies in rheumatology. RMD Open, 2018, 4, e000780.	3.8	16
117	Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. RMD Open, 2018, 4, e000766.	3.8	16
118	e10 Moderate to good construct validity of global presenteeism measures with multi-item presenteeism measure and patient-reported health outcomes. Rheumatology, 2018, 57, .	1.9	0
119	Are globals for health, well-being and quality of life interchangeable? A mixed methods study in ankylosing spondylitis patients and controls. Rheumatology, 2018, 57, 1555-1562.	1.9	3
120	Socio-economic gradients in the presence of musculoskeletal and other chronic diseases: results from a cross-sectional study in the Netherlands. Clinical Rheumatology, 2018, 37, 3173-3182.	2.2	4
121	Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply. Rheumatology, 2018, 57, 584-585.	1.9	3
122	An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity. Arthritis and Rheumatology, 2018, 70, 1557-1564.	5.6	17
123	Performance of the Michigan Hand Outcomes Questionnaire in hand osteoarthritis. Osteoarthritis and Cartilage, 2018, 26, 1627-1635.	1.3	13
124	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Annals of the Rheumatic Diseases, 2018, 77, 1311-1317.	0.9	85
125	Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 2018, 77, 1303-1310.	0.9	18
126	Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Rheumatology, 2018, 57, 1641-1650.	1.9	34

#	Article	IF	CITATIONS
127	Disease and management beliefs of elderly patients with rheumatoid arthritis and comorbidity: a qualitative study. Clinical Rheumatology, 2018, 37, 2367-2372.	2.2	11
128	AB1449-HPRâ€Patient factors contributing to and shared decision making in starting/switching biologics spondyloarthritis. , 2018, , .		0
129	FRI0660â€Usefulness of michigan hand outcomes questionnaire (MHQ) in hand osteoarthritis. , 2018, , .		Ο
130	FRI0024â€Do age and education influence the disease activity score? an explorative analysis in the norwegian cohort study nor-dmard. , 2018, , .		0
131	AB1043â€The clinical profile of gout significantly differs between male and female. , 2018, , .		0
132	AB0959â€Consumption of dairy products in relation to presence of clinical knee osteoarthritis: the maastricht study. , 2018, , .		0
133	AB1294â€Impact of work status on health-related quality of life (HRQOL) in ra. , 2018, , .		Ο
134	FRI0060â€Are older ra patients frail, or lonely and depressed?. , 2018, , .		0
135	The eumusc.net standards of care for rheumatoid arthritis: importance and current implementation according to patients and healthcare providers in the Netherlands. Clinical and Experimental Rheumatology, 2018, 36, 275-283.	0.8	1
136	Socio-economic inequalities in occurrence and health care costs in rheumatic and musculoskeletal diseases: results from a Spanish population-based study including 1.9 million persons. Clinical and Experimental Rheumatology, 2018, 36, 589-594.	0.8	3
137	Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group. Journal of Rheumatology, 2017, 44, 1727-1733.	2.0	12
138	Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology, 2017, 56, 1167-1176.	1.9	26
139	Work outcome in persons with musculoskeletal diseases: comparison with other chronic diseases & the role of musculoskeletal diseases in multimorbidity. BMC Musculoskeletal Disorders, 2017, 18, 10.	1.9	21
140	OMERACT Quality-adjusted Life-years (QALY) Working Group: Do Current QALY Measures Capture What Matters to Patients?. Journal of Rheumatology, 2017, 44, 1899-1903.	2.0	12
141	Construct Validity of Radiographs of the Feet to Assess Joint Damage in Patients with Gout. Journal of Rheumatology, 2017, 44, 91-94.	2.0	1
142	Patient-reported Flares in Ankylosing Spondylitis: A Cross-sectional Analysis of 234 Patients. Journal of Rheumatology, 2017, 44, 425-430.	2.0	15
143	SAT0531â€Matrix assisted laser desorption ionization imaging mass spectrometry applied to human osteoarthritis cartilage reveals the intra-tissue metabolic heterogeneity. , 2017, , .		0
144	FRI0430â€Dual trajectories of disease activity and health-related quality of life in patients with ankylosing spondylitis. , 2017, , .		0

#	Article	IF	CITATIONS
145	Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet, The, 2017, 390, 959-968.	13.7	253
146	Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. Journal of Rheumatology, 2017, 44, 1544-1550.	2.0	21
147	An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group. Journal of Rheumatology, 2017, 44, 1734-1739.	2.0	9
148	Clinicians' perspective on key domains in ANCA-associated vasculitis: a Delphi exercise. Scandinavian Journal of Rheumatology, 2017, 46, 112-117.	1.1	7
149	THU0603â€Disease burden of knee osteoarthritis patients undergoing joint replacement compared to matched controls: a population-based analysis of a dutch medical claims database. , 2017, , .		0
150	THU0689â€Moderate to good construct validity of global presenteeism measures with multi-item presenteeism measure and patient reported health outcomes: eular-pro worker productivity study. , 2017, , .		0
151	AB0685â€Secukinumab provides sustained improvements in work productivity and health related quality of life in patients with ankylosing spondylitis: long-term results from measure 1 and measure 2. , 2017, , .		1
152	THU0602â€Worker productivity loss remains a major issue for patients with inflammatory arthritis and osteoarthritis: results from the international eular-pro worker productivity study. , 2017, , .		0
153	Large country differences in work outcomes in patients with RA – an analysis in the multinational study COMORA. Arthritis Research and Therapy, 2017, 19, 216.	3.5	20
154	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody–associated Vasculitis. Journal of Rheumatology, 2017, 44, 1529-1535.	2.0	25
155	Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Annals of the Rheumatic Diseases, 2016, 75, 203-209.	0.9	66
156	Severity of Diabetes Mellitus and Total Hip or Knee Replacement. Medicine (United States), 2016, 95, e3739.	1.0	24
157	Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case–control study. British Journal of Clinical Pharmacology, 2016, 81, 370-378.	2.4	18
158	THU0378â€How Frequent Were Patient Reported Flares in Ankylosing Spondylitis Patients before The Wide Use of antiTNF and What Is The Validity of Patient Reported Flares? A Cross-Sectional Analysis of 234 Patients. Annals of the Rheumatic Diseases, 2016, 75, 324.1-324.	0.9	0
159	Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment. Osteoporosis International, 2016, 27, 2697-2707.	3.1	4
160	Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. Rheumatology, 2016, 55, 2014-2022.	1.9	15
161	OP0084â€Validation of The Asas Health Index: Results of A Multicenter International Study in 23 Countries: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 86.2-86.	0.9	0
162	Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages. RMD Open, 2016, 2, e000311.	3.8	31

#	Article	IF	CITATIONS
163	Changes in the clinical presentation of patients with rheumatoid arthritis from the early 1990s to the years 2010: earlier identification but more severe patient reported outcomes. Annals of the Rheumatic Diseases, 2016, 75, 2054-2056.	0.9	20
164	Global Prevalence of Spondyloarthritis: A Systematic Review and Metaâ€Regression Analysis. Arthritis Care and Research, 2016, 68, 1320-1331.	3.4	252
165	Work Outcome in Patients With Ankylosing Spondylitis: Results From a 12â€Year Followup of an International Study. Arthritis Care and Research, 2016, 68, 544-552.	3.4	35
166	Knowledge, illness perceptions and stated clinical practice behaviour in management of gout: a mixed methods study in general practice. Clinical Rheumatology, 2016, 35, 2053-2061.	2.2	25
167	The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskeletal Disorders, 2016, 17, 184.	1.9	103
168	The development of a personalized patient education tool for decision making for postmenopausal women with osteoporosis. Osteoporosis International, 2016, 27, 2489-2496.	3.1	12
169	Resource utilisation and direct costs in patients with recently diagnosed fibromyalgia who are offered one of three different interventions in a randomised pragmatic trial. Clinical Rheumatology, 2016, 35, 1307-1315.	2.2	7
170	Social Role Participation in Patients With Ankylosing Spondylitis: A Crossâ€ S ectional Comparison With Population Controls. Arthritis Care and Research, 2016, 68, 1899-1905.	3.4	15
171	Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study. Annals of the Rheumatic Diseases, 2016, 75, 540-546.	0.9	67
172	Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. Rheumatology, 2016, 55, 1217-1224.	1.9	31
173	In rheumatoid arthritis, country of residence has an important influence on fatigue: results from the multinational COMORA study. Rheumatology, 2016, 55, 735-744.	1.9	26
174	Content validity of global measures for at-work productivity in patients with rheumatic diseases: an international qualitative study. Rheumatology, 2016, 55, 1364-1373.	1.9	28
175	Test-retest Reliability and Correlations of 5 Global Measures Addressing At-work Productivity Loss in Patients with Rheumatic Diseases. Journal of Rheumatology, 2016, 43, 433-439.	2.0	19
176	In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study. Annals of the Rheumatic Diseases, 2016, 75, 715-720.	0.9	41
177	The importance of †state-of-the-art' cost-of-illness studies. Comment on: The economic burden of gout: A systematic review. Seminars in Arthritis and Rheumatism, 2016, 45, e9.	3.4	2
178	OMERACT Filter Evidence Supporting the Measurement of At-work Productivity Loss as an Outcome Measure in Rheumatology Research. Journal of Rheumatology, 2016, 43, 214-222.	2.0	42
179	Implementation of recommended non-pharmacotherapy in rheumatology practice: need for improvement. Clinical and Experimental Rheumatology, 2016, 34, S15-7.	0.8	0
180	Electronic assessment of disease activity and functioning in patients with axial spondyloarthritis: challenges and unmet needs. Clinical and Experimental Rheumatology, 2016, 34, S57-S61.	0.8	5

#	Article	IF	CITATIONS
181	Mapping of the Outcome Measures in Rheumatology Core Set for Antineutrophil Cytoplasmic Antibodyâ€Associated Vasculitis to the International Classification of Function, Disability and Health. Arthritis Care and Research, 2015, 67, 255-263.	3.4	9
182	Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open, 2015, 1, e000153.	3.8	85
183	Do patients with ankylosing spondylitis adapt to their disease? Evidence from a 'then-test' in patients treated with TNF inhibitors. RMD Open, 2015, 1, e000164-e000164.	3.8	1
184	Identification of antithrombotic drugs related to total joint replacement using anonymised free-text notes: a search strategy in the Clinical Practice Research Datalink. BMJ Open, 2015, 5, e009017.	1.9	2
185	Longitudinal Analyses of Presenteeism and Its Role as a Predictor of Sick Leave in Patients With Ankylosing Spondylitis. Arthritis Care and Research, 2015, 67, 1578-1585.	3.4	17
186	Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-1± antagonists in management of ankylosing spondylitis: a dynamic population modelling study. Cost Effectiveness and Resource Allocation, 2015, 13, 18.	1.5	4
187	Importance of Contextual Factors When Measuring Work Outcome in Ankylosing Spondylitis: A Systematic Review by the OMERACT Worker Productivity Group. Arthritis Care and Research, 2015, 67, 1316-1327.	3.4	31
188	The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Annals of the Rheumatic Diseases, 2015, 74, 1373-1378.	0.9	126
189	Understanding Limitations in At-work Productivity in Patients with Active Ankylosing Spondylitis: The Role of Work-related Contextual Factors. Journal of Rheumatology, 2015, 42, 93-100.	2.0	30
190	Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls. Journal of Rheumatology, 2015, 42, 2369-2375.	2.0	25
191	Individuals With Type 2 Diabetes Mellitus Are at an Increased Risk of Gout But This Is Not Due to Diabetes. Medicine (United States), 2015, 94, e1358.	1.0	30
192	The burden of non-radiographic axial spondyloarthritis. Seminars in Arthritis and Rheumatism, 2015, 44, 556-562.	3.4	112
193	Cost of Illness and Determinants of Costs Among Patients with Gout. Journal of Rheumatology, 2015, 42, 335-344.	2.0	18
194	Health literacy in patients dealing with gout: a qualitative study. Clinical Rheumatology, 2015, 34, 1599-1603.	2.2	26
195	Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making. Journal of Rheumatology, 2015, 42, 2442-2447.	2.0	22
196	A Review of Patient Preferences for Osteoporosis Drug Treatment. Current Rheumatology Reports, 2015, 17, 61.	4.7	35
197	Content and construct validity of the Rheumatic Diseases Comorbidity Index in patients with gout. Rheumatology, 2015, 54, 1659-1663.	1.9	26
198	Socioeconomic inequities in perceived health among patients with musculoskeletal disorders compared with other chronic disorders: results from a cross-sectional Dutch study. RMD Open, 2015, 1, e000045-e000045.	3.8	21

#	Article	IF	CITATIONS
199	Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study. RMD Open, 2015, 1, e000041-e000041.	3.8	57
200	Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. Journal of Rheumatology, 2015, 42, 2190-2197.	2.0	62
201	Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody–associated Vasculitis Using the OMERACT Process. Journal of Rheumatology, 2015, 42, 2204-2209.	2.0	22
202	Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures. Journal of Rheumatology, 2015, 42, 2448-2459.	2.0	21
203	Determinants of the prevalence of gout in the general population: a systematic review and meta-regression. European Journal of Epidemiology, 2015, 30, 19-33.	5.7	45
204	Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project. Annals of the Rheumatic Diseases, 2015, 74, 1145-1149.	0.9	68
205	Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Annals of the Rheumatic Diseases, 2015, 74, 830-835.	0.9	161
206	Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases, 2015, 74, 65-73.	0.9	311
207	FRIO222â€Translation and Cross-Cultural Adaptation of the ASAS Health Index and the Environmental Item Set into 15 Languages. Annals of the Rheumatic Diseases, 2014, 73, 463.1-463.	0.9	2
208	Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study. BMJ Open, 2014, 4, e005246-e005246.	1.9	18
209	THU0097â€Work Participation in A Large Cohort of Patients with Axial Spondyloarthritis and Non-Specific Chronic Low Back Pain: Table 1. Annals of the Rheumatic Diseases, 2014, 73, 210.2-210.	0.9	0
210	Problems in Work Participation and Resource Use Should Not Be Underestimated in Patients with Early Spondyloarthritis. Journal of Rheumatology, 2014, 41, 2413-2420.	2.0	14
211	Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?. Annals of the Rheumatic Diseases, 2014, 73, 2010-2021.	0.9	90
212	Understanding Presenteeism in Patients With Ankylosing Spondylitis: Contributing Factors and Association With Sick Leave. Arthritis Care and Research, 2014, 66, 916-924.	3.4	23
213	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014, 44, 271-282.	3.4	29
214	Physical Functioning in Patients With Ankylosing Spondylitis. Journal of Clinical Rheumatology, 2014, 20, 133-137.	0.9	12
215	Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Research and Therapy, 2014, 16, R36.	3.5	44
216	Effects of Cardiovascular Comorbidities on Work Participation in Rheumatic Diseases: A Prospective Cohort Study Among Working Individuals. Arthritis Care and Research, 2014, 66, 157-163.	3.4	7

#	Article	IF	CITATIONS
217	Do the Us Panel Recommendations Hold for Europe? Investigating the Relation Between Quality of Life Versus Work-Status, Absenteeism and Presenteeism. Value in Health, 2014, 17, A549.	0.3	0
218	Inequities in access to biologic and synthetic DMARDs across 46 European countries. Annals of the Rheumatic Diseases, 2014, 73, 198-206.	0.9	289
219	Pattern of bone erosion and bone proliferation in psoriatic arthritis hands: a high-resolution computed tomography and radiography follow-up study during adalimumab therapy. Scandinavian Journal of Rheumatology, 2014, 43, 202-208.	1.1	14
220	No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial. Rheumatology, 2014, 53, 746-756.	1.9	34
221	The cross-sectional association between uric acid and atherosclerosis and the role of low-grade inflammation: the CODAM study. Rheumatology, 2014, 53, 2053-2062.	1.9	24
222	FRI0152â€Decreased Employment, Work Productivity, and Presenteeism in Patients with Ankylosing Spondylitis is Associated with Increased Disease Activity as Measured by Basdai: Table 1 Annals of the Rheumatic Diseases, 2014, 73, 437.2-437.	0.9	0
223	THU0069â€The Epidemiology of Extra-Articular Manifestations in Ankylosing Spondylitis: A Population-Based Matched Cohort Study. Annals of the Rheumatic Diseases, 2014, 73, 200.3-200.	0.9	3
224	THU0090â€Cardiovascular Morbidity in Patients with Ankylosing Spondylitis: A Population-Based Cohort Study. Annals of the Rheumatic Diseases, 2014, 73, 207.3-208.	0.9	1
225	The ASAS Health Index (ASAS HI) - a new tool to assess the health status of patients with spondyloarthritis. Clinical and Experimental Rheumatology, 2014, 32, S-105-8.	0.8	17
226	Tumor Necrosis Factor α Inhibition in Radiographic and Nonradiographic Axial Spondyloarthritis: Results From a Large Observational Cohort. Arthritis and Rheumatism, 2013, 65, 3096-3106.	6.7	129
227	SAT0260â€Understanding limitations in at-work productivity in patients with active as: Larger contribution from medical factors compared to work related factors:. Annals of the Rheumatic Diseases, 2013, 71, 559.3-560.	0.9	0
228	OP0014â€The Omeract-Ramris Rheumatoid Arthritis Magnetic Resonance Imaging Joint Space Narrowing Score (RAMRIS JSN) is Reproducible and Correlates Closely with Computed Tomography Assessment. Annals of the Rheumatic Diseases, 2013, 72, A52.3-A52.	0.9	1
229	THU0365â€Work Productivity in a Cohort of Employed Ankylosing Spondylitis Patients Treated with Etanercept. Annals of the Rheumatic Diseases, 2013, 72, A289.1-A289.	0.9	0
230	AB1307â€Intra- and interreader reliability of the omeract joint space narrowing score on magnetic resonance imaging and computed tomography in rheumatoid arthritis wrist and metacarpophalangeal joints. Annals of the Rheumatic Diseases, 2013, 71, 712.10-712.	0.9	0
231	THU0359â€A bio-psycho-social approach for assessing associations with changes in perceived health in recently diagnosed fibromyalgia patients. Annals of the Rheumatic Diseases, 2013, 71, 277.1-277.	0.9	0
232	FRI0433â€Does cardiovascular disease increase the risk of sick leave and work disability among patients with rheumatic disease?. Annals of the Rheumatic Diseases, 2013, 71, 460.3-461.	0.9	0
233	FRI0405â€Simultaneously forecasting burden of illness and cost-effectiveness: The case of tumour necrosis factor-alpha antagonist for ankylosing spondylitis in the dutch society. Annals of the Rheumatic Diseases, 2013, 71, 451.2-451.	0.9	0
234	Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Preference and Adherence, 2013, 7, 133.	1.8	87

#	Article	IF	CITATIONS
235	AB1350â€Is cardiovascular morbidity and mortality increased in working individuals with inflammatory rheumatic diseases?. Annals of the Rheumatic Diseases, 2013, 71, 715.3-715.	0.9	Ο
236	The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Annals of the Rheumatic Diseases, 2012, 71, 161-171.	0.9	82
237	Epidemiology of Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 441-476.	1.9	177
238	Effect of biological therapy on work participation in patients with ankylosing spondylitis: a systematic review. Annals of the Rheumatic Diseases, 2012, 71, 1924-1933.	0.9	36
239	Assessing the impact of musculoskeletal health conditions using the International Classification of Functioning, Disability and Health. Disability and Rehabilitation, 2011, 33, 1281-1297.	1.8	16
240	The burden of illness of rheumatoid arthritis. Clinical Rheumatology, 2011, 30, 3-8.	2.2	106
241	Large Epidemiologic Studies of Gout: Challenges in Diagnosis and Diagnostic Criteria. Current Rheumatology Reports, 2011, 13, 167-174.	4.7	16
242	Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPSâ€RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RAâ€WIS), Work Limitations Questionnaire (WLQ), and Work Productivity and Activity Impairment Questionnaire (WPAI). Arthritis Care and Research, 2011, 63, S337-49.	3.4	100
243	Developing and validating an index for measuring health in patients with ankylosing spondylitis. Rheumatology, 2011, 50, 894-898.	1.9	18
244	Valuing Health for Clinical and Economic Decisions: Directions Relevant for Rheumatologists. Journal of Rheumatology, 2011, 38, 1770-1775.	2.0	13
245	Inflammatoir darmlijden en arbeidsparticipatie. Tijdschrift Voor Bedrijfs- En Verzekeringsgeneeskunde, 2010, 18, 127-128.	0.0	Ο
246	Measurement: function and mobility (focussing on the ICF framework). Best Practice and Research in Clinical Rheumatology, 2010, 24, 605-624.	3.3	6
247	ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Annals of the Rheumatic Diseases, 2010, 69, 102-107.	0.9	93
248	Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Annals of the Rheumatic Diseases, 2010, 69, 1123-1128.	0.9	110
249	Role of contextual factors in health-related quality of life in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2010, 69, 108-112.	0.9	40
250	Validity of the work productivity and activity impairment questionnaire - general health version in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R177.	3.5	175
251	Monitoring anti-TNFÂ treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage. Annals of the Rheumatic Diseases, 2009, 68, 1572-1579.	0.9	84
252	The OMERACT-ICF Reference Group: Integrating the ICF into the OMERACT Process: Opportunities and Challenges. Journal of Rheumatology, 2009, 36, 2057-2060.	2.0	25

#	Article	IF	CITATIONS
253	Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome. Journal of Rheumatology, 2009, 36, 1249-1255.	2.0	52
254	Aspects relevant for functioning in patients with ankylosing spondylitis according to the health professionals: a Delphi study with the ICF as reference. Rheumatology, 2009, 48, 997-1002.	1.9	26
255	The OMERACT Initiative. Towards a Reference Approach to Derive QALY for Economic Evaluations in Rheumatology. Journal of Rheumatology, 2009, 36, 2045-2049.	2.0	13
256	Which Aspects of Functioning Are Relevant for Patients with Ankylosing Spondylitis: Results of Focus Group Interviews. Journal of Rheumatology, 2009, 36, 2501-2511.	2.0	23
257	Same question, different answers: a comparison of global health assessments using visual analogue scales. Quality of Life Research, 2009, 18, 1285-1292.	3.1	13
258	Towards an ICF-based clinical measure of functioning in people with ankylosing spondylitis: A methodological exploration. Disability and Rehabilitation, 2009, 31, 528-537.	1.8	32
259	The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. Clinical and Experimental Rheumatology, 2009, 27, S112-7.	0.8	32
260	Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clinical and Experimental Rheumatology, 2009, 27, S118-23.	0.8	60
261	Reliability of the ICF Core Set for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 1078-1084.	0.9	71
262	The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Annals of the Rheumatic Diseases, 2007, 66, 1072-1077.	0.9	103
263	The international classification for functioning, disability and health. Clinical Rheumatology, 2007, 26, 1803-1808.	2.2	16
264	The World Health Organisation International Classification of Functioning, Disability and Health: a conceptual model and interface for the OMERACT process. Journal of Rheumatology, 2007, 34, 600-6.	2.0	48
265	Worker productivity outcome measures in arthritis. Journal of Rheumatology, 2007, 34, 1372-80.	2.0	90
266	A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nature Clinical Practice Rheumatology, 2006, 2, 546-553.	3.2	83
267	Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. Journal of Rheumatology, 2006, 33, 2475-83.	2.0	68
268	The burden of ankylosing spondylitis. Journal of rheumatology Supplement, The, 2006, 78, 4-11.	2.2	115
269	Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clinical Rheumatology, 2005, 24, 615-619.	2.2	18
270	Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone. Journal of Rheumatology, 2004, 31, 1709-16.	2.0	22

#	Article	IF	CITATIONS
271	Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Annals of the Rheumatic Diseases, 2003, 62, 1178-1184.	0.9	167
272	Ankylosing spondylitis: an overview. Annals of the Rheumatic Diseases, 2002, 61, 8iii-18.	0.9	496
273	Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Annals of the Rheumatic Diseases, 2002, 61, 429-437.	0.9	182
274	Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Annals of the Rheumatic Diseases, 2001, 60, 353-358.	0.9	181
275	Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2001, 60, 1033-1039.	0.9	164
276	THU0140â€Rheumatoid arthritis (ra) in vilnius and oslo: a comparison regarding disease and health measures. , 2001, , .		1
277	THU0152â€The disease activity score predicts radiological progression during the following 6 months of observation in a 5 years observational study; an example of advanced longitudinal data analysis. , 2001, , .		1
278	Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet, The, 1997, 350, 309-318.	13.7	949
279	Is SAPHO syndrome a spondylarthropathy? A vasculopathy? Report of a case. Revue Du Rhumatisme: Joint, Bone, Spine Diseases, 1997, 64, 424-7.	0.0	0